11ukM

London Quick Take – 29 September – Gold hits fresh record as FTSE 100 nears all-time high as GSK and AZN rise on strategic moves

Equities 3 minutes to read
Neil Wilson
Neil Wilson

Investor Content Strategist

Note: This is marketing material. This article is not investment advice, capital is at risk.

Key Points

  • FTSE 100 nears record as GSK and AstraZeneca make strategic moves
  • Sterling, euro and yen all sharply higher versus the US dollar as US Treasury yields slip 
  • President Trump to meet Congressional leaders as US government shutdown looms
  • Labour Party conference begins with Chancellor Rachel Reeves due to speak

Long story short: Gold rallied to a fresh record and the FTSE 100 climbed near its all-time high early on Monday, buoyed by gains for GSK and AstraZeneca as the two pharma giants make long-term strategic moves. It's a weak dollar day which is usually good for risk.

Shutdown fears: If Congress fails to pass a spending bill by midnight of 30 September, parts of the US federal government will begin shutting down. It would be the fifth shutdown of the 21st century. Donald Trump is set to meet top Republican and Democrat Congressional leaders - it 's still not clear if these talks will likely avert a shutdown.

Markets tend to look through these events, but it could be trickier this time. Spot gold hit a fresh record high above $3,800/oz and silver cleared a fresh 14yr peak while the dollar sank and Treasury yields slipped - I'm not sure sowing a 'shutdown fears' narrative - perhaps a general ennui about the debt burden in the US, de-dollarisation, the old 4D trade (debt debasement, dollar devaluation) etc, etc. Ultimately, the budget impasse holds a mirror up to longer-term concerns about fiscal deficits and unsustainable spending. Something we know all about here in Britain. Sterling jumped after hitting its weakest in two months at the end of last week, while the yen eased back from the important 150 level. 

Usually, markets ignore shutdowns – most last only a few days and investors seem to take a long-term view of the situation, and the short duration of most incidents has little impact on company profits. The average length of shutdowns is eight days. In 12 of the 21 shutdowns the S&P 500 has risen during the event. It could be different this time... arguably the main annoyance could be to delay the BLS's nonfarm payrolls report, which is due on Friday. More on that below.

Pharma shakeup: AstraZeneca, sometimes the largest listed name on the London Stock Exchange, will list its shares directly in New York. It’s being billed simplification of its listing structure and will undoubtedly improve liquidity, but it’s also a bit of a knock-back for London. Shares climbed on the news - can it get the best of both worlds? It wants to improve visibility and tap the deeper markets of the US while retaining its British and Swedish DNA. I think there is probably relief that it’s not pursuing a primary listing in New York, but the decision is hardly a ringing endorsement of London. It reflects the fundamental, structural issues in the UK for the largest globally-oriented stocks - the depth and liquidity of its capital markets is falling short of what's on offer across the pond.

Meanwhile Emma Walmsley will step down as CEO at GSK after nine years in charge. Shares rose on the news by over 3% - Walmsley copped flak for years, but the stock has traded sideways for two decades and things have been improving. The business looks well positioned after some notable progress in the year or so, particularly the spin-off of Haleon and strong cancer drug sales. Tariff uncertainty should start clearing, too. Seems like both GSK and AZN are laying down some long-term markers for the future.

Shares traded higher early doors in London with the FTSE 100 up 0.7% to 9,352, led by GSK and supported by the precious metal miners, who again rallied along with gold to nudge the blue chips to withing a fraction of a record high. Meanwhile shares were broadly higher in Europe. Wall Street closed higher on Friday, ending a tough weak on a more positive note as PCE inflation printed in line. Futures are pointing higher again.

Chancellor Rachel Reeves speaks today at the Labour party conference – watch for plenty of market-soothing talk after last week’s rise in yields. Prime minister Keir Starmer refused to rule out a VAT hike...it's all about not being in hock to the markets. Check out our piece on the UK's fiscal outlook.

Elsewhere, the Trump administration is said to be contemplating the imposition of tariffs on imported electronic devices, with the rate to be decided on the number of chips.

Nonfarm payrolls is the main event this week after a slate-full of US employment data coming up with the JOLTS job openings report, ADP payrolls data and weekly unemployment claims. A very weak jobs report for August sealed the deal on the Fed’s rate cut in September. But more recent data has been positive, clouding the market outlook on how many cuts the FOMC will go for this year. August saw just 22k jobs added, well below forecast, whilst the unemployment rate edged up to 4.3%. Markets expect just 39,000 jobs were added in September, with unemployment steady from the month before. 

 

Outrageous Predictions 2026

01 /

  • Executive Summary: Outrageous Predictions 2026

    Outrageous Predictions

    Executive Summary: Outrageous Predictions 2026

    Saxo Group

    Read Saxo's Outrageous Predictions for 2026, our latest batch of low probability, but high impact ev...
  • A Fortune 500 company names an AI model as CEO

    Outrageous Predictions

    A Fortune 500 company names an AI model as CEO

    Charu Chanana

    Chief Investment Strategist

    Can AI be trusted to take over in the boardroom? With the right algorithms and balanced human oversi...
  • Dollar dominance challenged by Beijing’s golden yuan

    Outrageous Predictions

    Dollar dominance challenged by Beijing’s golden yuan

    Charu Chanana

    Chief Investment Strategist

    Beijing does an end-run around the US dollar, setting up a framework for settling trade in a neutral...
  • Obesity drugs for everyone – even for pets

    Outrageous Predictions

    Obesity drugs for everyone – even for pets

    Jacob Falkencrone

    Global Head of Investment Strategy

    The availability of GLP-1 drugs in pill form makes them ubiquitous, shrinking waistlines, even for p...
  • Dumb AI triggers trillion-dollar clean-up

    Outrageous Predictions

    Dumb AI triggers trillion-dollar clean-up

    Jacob Falkencrone

    Global Head of Investment Strategy

    Agentic AI systems are deployed across all sectors, and after a solid start, mistakes trigger a tril...
  • Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Outrageous Predictions

    Quantum leap Q-Day arrives early, crashing crypto and destabilizing world finance

    Neil Wilson

    Investor Content Strategist

    A quantum computer cracks today’s digital security, bringing enough chaos with it that Bitcoin crash...
  • SpaceX announces an IPO, supercharging extraterrestrial markets

    Outrageous Predictions

    SpaceX announces an IPO, supercharging extraterrestrial markets

    John J. Hardy

    Global Head of Macro Strategy

    Financial markets go into orbit, to the moon and beyond as SpaceX expands rocket launches by orders-...
  • Taylor Swift-Kelce wedding spikes global growth

    Outrageous Predictions

    Taylor Swift-Kelce wedding spikes global growth

    John J. Hardy

    Global Head of Macro Strategy

    Next year’s most anticipated wedding inspires Gen Z to drop the doomscrolling and dial up the real w...
  • Britain’s Great EU Backdoor Return

    Outrageous Predictions

    Britain’s Great EU Backdoor Return

    Neil Wilson

    Investor Content Strategist

    Faced with rolling fiscal, economic, trade and political crises the UK government sneaks back into t...
  • Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    Outrageous Predictions

    Despite concerns, U.S. 2026 mid-term elections proceed smoothly

    John J. Hardy

    Global Head of Macro Strategy

    In spite of outstanding threats to the American democratic process, the US midterms come and go cord...

This content is marketing material. 

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Market Ltd. (SCML) provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice or a recommendation.

SCML content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

SCML partners with companies that provide compensation for promotional activities conducted on its platform. Some partners also pay retrocessions contingent on clients investing in products from those partners. 

While SCML receives compensation from these partnerships, all educational and research content remains focused on providing information to clients.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. SCML does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer and notification on non-independent investment research for more details.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992